| Identification | Back Directory | [Name]
OSELTAMIVIR ACID | [CAS]
187227-45-8 | [Synonyms]
Gs4071
Gs-4071
Gs 4071
Aids095377
Aids-095377
Oseltamivir impurity C
Oseltamivir acid, >=98%
Oseltamivir carboxylate
Oseltamivir EP Impurity C
OseltaMivir carboxylic acid
Oseltamivir carboxylate (OC)
204255-11-8 (Monophospate salt)
Oseltamivir Phosphate impurity C (EP)
Oseltamivir carboxylate (OC),Metabolite of oseltamivir
(3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid
(3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid
(3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohex-ene-1-carboxylic acid
1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, (3R,4R,5S)-
OseltamivirCarboxylicAcid,4-(Acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexence-1-carboxylicAcid | [Molecular Formula]
C14H24N2O4 | [MDL Number]
MFCD00953940 | [MOL File]
187227-45-8.mol | [Molecular Weight]
284.354 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Oseltamivir Acid is a metabolite of Oseltamivir (O701000). | [Definition]
ChEBI: A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). A
antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza. | [Description]
Oseltamivir (GS-4104) is an antiviral prodrug targeted against the influenza viruses.1,2 Oseltamivir acid is the active metabolite of oseltamivir.3,4 It acts as an inhibitor of influenza neuraminidases A and B (IC50 = 0.1 to 4.9 nM for both enzymes), in this way preventing virus budding and release.5,6,7 | [References]
[1] enguang feng, deju ye, jian li, dengyou zhang, jinfang wang, fei zhao, rolf hilgenfeld, mingyue zheng, hualiang jiang and hong liu. recent advances in neuraminidase inhibitor development as anti-influenza drugs. chem med chem 2012, 7: 1527 – 1536.
[2] tom jefferson reviewer, mark jones, peter doshi, elizabeth a spencer, igho onakpoya, carl j heneghan. oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comment. bmj. 2014, 348: g2545.
[3] rashmi dixit, gulam khandaker, scott ilgoutz, harunor rashid and robert booy. emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. infectious disorders – drug targets. 2013, 13 (1): 34-45. |
|
|